US2012071455A1PendingUtilityA1

6-substituted demethyl-estradiol derivatives as selective er-beta agonists

44
Assignee: YARGER JAMES GPriority: Sep 14, 2010Filed: Sep 14, 2011Published: Mar 22, 2012
Est. expirySep 14, 2030(~4.2 yrs left)· nominal 20-yr term from priority
Inventors:James G. YargerSteven H. Nye
A61P 43/00A61P 25/04A61P 29/00C07J 41/0044C07J 17/00C07J 41/0016A61K 31/56C07J 51/00C07J 31/006C07J 1/007C07J 1/0074C07J 1/0059A61K 31/565C07J 1/00
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are 6-substituted 13-demethyl-estradiol derivatives as selective ERβ agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A compound of formula: 
       
         
           
           
               
               
           
         
         wherein 
         R 1 , R 2 , R 3  and R 4  are independently selected from hydrogen, C 1 -C 6  alkyl, halo, a sulfate, a glucuronide, —OH, a bulky group, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, —N(CH 2 ) n , a phosphate group, and a phosphinate group; 
         R 11  is selected from H, C 1 -C 6  alkyl, halogen, a sulfate, a glucoronide, —SO 2 NH 2 , —COOH, —CN, —CH 2 CN—, —NHCN—, —CHO, ═CHOCH 3 , —COO salt, —OSO 2 alkyl, —NH 2 , and —NHCO(CH 2 ) n ; 
         X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, C 2 -C 12  alkynyl, halogen, a glucoronide, —NH 2 , —SO 2 NH 2 , —COOH, —CN, —CH 2 CN, —NHCN, —CHO, —COOsalt, —OSO 2 alkyl, —SH, —SCH 3 , —CH[(CH 2 ) n CH 3 ]COOCH 3 , —(CH 2 ) m COOCH 3 , —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , (CH 2 ) m —S—CH 3 , —(CH 2 ) m —S—(CH 2 ) n CH 3 , —(CH 2 ) m —NH—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-N—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-N—(CH 2 ) n CH 3 , —(CH 2 ) m —OH, —(CH 2 ) m —O—NH 2 , —(CH 2 ) m —S—NH 2 , —NH(CH 2 ) m CH 3 , —NH(CH 2 ) m OCH 3 , —NH(CH 2 ) m CHOH—COOH, —N(CH 3 ) 2 , —(CH 2 ) m (NH)CH 2 OH, —NHCOOH, —(CH 2 ) m NHCOOH, —NO 2 , —SCN, —SO 2 alkyl, —B(OH) 2 , —(CH 2 ) m N(CH 3 )—SO 2 —NH 3 , —(CH 2 ) m —NH—SO 2 —NH 2 , —NHC(═S)CH 3 , and —NHNH 2 ; 
         Y is selected from hydrogen, ═O, —OCO(R 6 ) and —OH; 
         m is an integer between 0-20; 
         n is an integer between 0-8; 
         the   symbol represents either a single or a double bond capable of forming a keto group at position 3 or 17; and 
         the   symbol represents any type of bond regardless of the stereochemistry; 
         and the respective enantiomers, stereochemical isomers, hydrates, solvates, tautomers and pharmaceutically acceptable salts thereof. 
       
     
     
         2 . A compound according to  claim 1  having the formula: 
       
         
           
           
               
               
           
         
       
     
     
         3 . A compound according to  claim 2  wherein
 Y is selected from ═O or —OH; 
 R 4  is selected from hydrogen, halo and C 1 -C 6  alkyl; 
 R 2  is selected from hydrogen, —OH and halo; 
 R 3  is selected from hydrogen, halo and —OH; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m COOCH 3 , —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , (CH 2 ) m —S—CH 3 , —(CH 2 ) m —S—(CH 2 ) n CH 3 , —(CH 2 ) m —N—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-N—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-N—(CH 2 ) n CH 3 , —(CH 2 ) m —OH, —(CH 2 ) m —O—NH 2 , —(CH 2 ) m —S—NH 2 , —NH(CH 2 ) m CH 3 , —NH(CH 2 ) m OCH 3 , —NH(CH 2 ) m CHOH—COOH, —(CH 2 ) m (NH)CH 2 OH, —(CH 2 ) m NHCOOH, —(CH 2 ) m N(CH 3 )—SO 2 —NH 3 , and —(CH 2 ) m —NH—SO 2 —NH 2 ; 
 m is an integer from 1-20; 
 n is an integer from 0-8; and 
 the   symbol represents either a single or a double bond. 
 
     
     
         4 . A compound according to  claim 3  wherein
 Y is (S)-configured —OH; 
 R 4  is selected from hydrogen and alkyl; 
 R 2  and R 3  are hydrogen; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , (CH 2 ) m —S—CH 3 , and —(CH 2 ) m —S—(CH 2 ) n CH 3 ; 
 m is an integer from 1-6; 
 n is an integer from 0-3; and 
 the C-13 methyl group is (S)-configured. 
 
     
     
         5 . A compound according to  claim 1  having the formula: 
       
         
           
           
               
               
           
         
       
     
     
         6 . A compound according to  claim 5  wherein:
 R 2  is selected from hydrogen, —OH and halo; 
 R 4  is selected from hydrogen, halo or C 1 -C 6  alkyl; 
 R 2  is selected from hydrogen and halo; 
 R 3  is selected from hydrogen, halo and —OH; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m COOCH 3 , —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , (CH 2 ) m —S—CH 3 , —(CH 2 ) m —S—(CH 2 ) n CH 3 , —(CH 2 ) m —N—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-S—(CH 2 ) n CH 3 , C 2 -C 8  alkenyl-N—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-O—(CH 2 ) n CH 3 , C 2 -C 8  alkynyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-N—(CH 2 ) n CH 3 , —(CH 2 ) m —OH, —(CH 2 ) m —O—NH 2 , —(CH 2 ) m —S—NH 2 , —NH(CH 2 ) m CH 3 , NH(CH 2 ) m OCH 3 , —NH(CH 2 ) m CHOH—COOH, —(CH 2 ) m (NH)CH 2 OH, —(CH 2 ) m NHCOOH, —(CH 2 ) m N(CH 3 )—SO 2 —NH 3 , and —(CH 2 ) m —NH—SO 2 —NH 2 ; 
 m is an integer from 1-20; and 
 n is an integer from 0-8. 
 
     
     
         7 . A compound according to  claim 6  wherein:
 R 1  is hydrogen; 
 R 4  is selected from hydrogen or alkyl; 
 R 2  and R 3  are hydrogen; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , (CH 2 ) m —S—CH 3 , and —(CH 2 ) m —S—(CH 2 ) n CH 3 ; 
 m is an integer from 1-12; and 
 n is an integer from 0-4, 
 wherein both the C-13 methyl and C-17 hydroxyl are (S)-configured. 
 
     
     
         8 . A compound according to  claim 1  having the formula: 
       
         
           
           
               
               
           
         
       
     
     
         9 . A compound according to  claim 8  wherein:
 R 11  is selected from hydrogen and C 1 -C 6  alkyl; 
 R 4  is selected from hydrogen, halo and C 1 -C 6  alkyl; 
 R 2  is selected from hydrogen and halo; 
 R 3  is selected from hydrogen, halo and —OH; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m COOCH 3 , —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , —(CH 2 ) m —S—CH 3 , —(CH 2 ) m —S—(CH 2 ) n CH 3 , —(CH 2 ) m —N—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-N—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-N—(CH 2 ) n CH 3 , —(CH 2 ) m —OH, —(CH 2 ) m —O—NH 2 , —(CH 2 ) m —S—NH 2 , —NH(CH 2 ) m CH 3 , NH(CH 2 ) m OCH 3 , —NH(CH 2 ) m CHOH—COOH, —(CH 2 ) m (NH)CH 2 OH, —(CH 2 ) m NHCOOH, —(CH 2 ) m N(CH 3 )—SO 2 —NH 3 , and —(CH 2 ) m —NH—SO 2 —NH 2 ; 
 m is an integer from 1-20; and 
 n is an integer from 0-8. 
 
     
     
         10 . A compound according to  claim 9  wherein:
 R 11  is hydrogen; 
 R 4  is selected from hydrogen or alkyl; 
 R 2  and R 3  are hydrogen; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , —(CH 2 ) m —S—CH 3 , and —(CH 2 ) m —S—(CH 2 ) n CH 3 ; 
 m is an integer from 1-12; and 
 n is an integer from 0-4, 
 wherein both the C-13 methyl and C-17 hydroxyl are (S)-configured. 
 
     
     
         11 . A compound according to  claim 1  having the formula: 
       
         
           
           
               
               
           
         
       
     
     
         12 . A compound according to  claim 11  wherein:
 R 1  is selected from hydrogen, —OH and halo; 
 R 2  is selected from hydrogen and halo; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m COOCH 3 , —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , —(CH 2 ) m —S—CH 3 , —(CH 2 ) m —S—(CH 2 ) n CH 3 , —(CH 2 ) m —N—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-N—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-N—(CH 2 ) n CH 3 , —(CH 2 ) m —OH, —(CH 2 ) m —O—NH 2 , —(CH 2 ) m —S—NH 2 , —NH(CH 2 ) m CH 3 , NH(CH 2 ) m OCH 3 , —NH(CH 2 ) m CHOH—COOH, —(CH 2 ) m (NH)CH 2 OH, —(CH 2 ) m NHCOOH, —(CH 2 ) m N(CH 3 )—SO 2 —NH 3 , and —(CH 2 ) m —NH—SO 2 —NH 2 ; 
 m is an integer from 1-20; and 
 n is an integer from 0-8. 
 
     
     
         13 . A compound of  claim 12  wherein
 R 1  and R 2  are hydrogen; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , —(CH 2 ) m —S—CH 3 , and —(CH 2 ) m —S—(CH 2 ) n CH 3 ; 
 m is an integer from 1-12; and 
 n is an integer from 0-4, 
 wherein both the C-13 methyl and C-17 hydroxyl are (S)-configured. 
 
     
     
         14 . A compound according to  claim 1  having the formula: 
       
         
           
           
               
               
           
         
       
       wherein Z is selected from —O—, —S— and —NH—. 
     
     
         15 . A compound of  claim 14  wherein
 m is 1-12; 
 n is 0-4; 
 R 1  is selected from hydrogen, —OH and halo; 
 R 4  is selected from hydrogen, halo and C 1 -C 6  alkyl; 
 R 2  is selected from hydrogen and halo; 
 R 3  is selected from hydrogen, halo and —OH; and 
 Z is selected from —O— and —S—. 
 
     
     
         16 . A compound according to  claim 15  wherein
 m is 2-8; 
 n is 0-3; 
 R 1 -R 4  are hydrogen; and 
 Z is —O—, 
 wherein both the C-13 methyl and C-17 hydroxyl are (S)-configured. 
 
     
     
         17 . A compound according to  claim 1  having the formula: 
       
         
           
           
               
               
           
         
       
     
     
         18 . A compound according to  claim 17  wherein:
 R 1  is selected from hydrogen, —OH and halo; 
 R 4  is selected from hydrogen, halo and C 1 -C 6  alkyl 
 R 2  is selected from hydrogen and halo; 
 R 3  is selected from hydrogen, halo and —OH; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m COOCH 3 , —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) n CH 3 , —(CH 2 ) m —S—CH 3 , —(CH 2 ) m —S—(CH 2 ) n CH 3 , —(CH 2 ) m —N—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkenyl-N—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-O—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-S—(CH 2 ) n CH 3 , —C 2 -C 8  alkynyl-N—(CH 2 ) n CH 3 , —(CH 2 ) m —OH, —(CH 2 ) m —O—NH 2 , —(CH 2 ) m —S—NH 2 , —NH(CH 2 ) m CH 3 , NH(CH 2 ) m OCH 3 , —NH(CH 2 ) m CHOH—COOH, —(CH 2 ) m (NH)CH 2 OH, —(CH 2 ) m NHCOOH, —(CH 2 ) m N(CH 3 )—SO 2 —NH 3 , and —(CH 2 ) m —NH—SO 2 —NH 2 ; 
 m is an integer from 1-20; and 
 n is an integer from 0-8. 
 
     
     
         19 . A compound of  claim 18  wherein
 R 1 , R 2 , R 3  and R 4  are hydrogen; 
 X is selected from C 1 -C 12  alkyl, C 2 -C 12  alkenyl, —(CH 2 ) m —O—CH 3 , —(CH 2 ) m —O—(CH 2 ) m CH 3 , (CH 2 ) m —S—CH 3 , and —(CH 2 ) m —S—(CH 2 ) n CH 3 ; 
 m is an integer from 1-12; and 
 n is an integer from 0-4. 
 
     
     
         20 . A compound according to  claim 1  selected from
 a) (8S,9S,14S,17S)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 b) (6R,8S,9S,14S,17S)-6-(methoxymethyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 c) (6R,8S,9S,14S,17S)-6-(6-methoxyhexyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 d) (6R,8S,9S,14S,17S)-6-(hydroxymethyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 e) (6R,8S,9S,14S,17S)-6-((aminooxy)methyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 f) (6R,8S,9S,14S,17S)-6-(((methoxymethyl)amino)methyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 g) methyl(((6R,8S,9S,14S,17S)-3,17-dihydroxy-13-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-yl)methyl)carbamate; 
 h) (6R,8S,9S,14S,17S)-6-methoxy-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 i) (6R,8S,9S,14S,17S)-6-(2-methoxyethyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 j) (6R,8S,9S,14S,17S)-6-(4-methoxybutyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 k) (6R,8S,9S,14S,17S)-6-(8-methoxyoctyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 
 l) (6R,8S,9S,14S,17S)-3-hydroxy-6-(methoxymethyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl stearate; 
 m) (6R,8S,9S,14S,17S)-6-(4-propoxybutyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; and 
 n) (6R,8S,9S,14S,17S)-6-(5-ethoxypentyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol. 
 
     
     
         21 . A method of treating pain in a host in need of such treatment, the method comprising administering to the host a therapeutically effective amount of a compound of  claim 1 . 
     
     
         22 . The method of  claim 21  wherein the mammalian host is a human. 
     
     
         23 . A method according to  claim 21  wherein the compound selectively binds to the ER-β receptor. 
     
     
         24 . A pharmaceutical composition comprising a compound of  claim 1  and a pharmaceutically-acceptable carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.